-
Other Similar Measures? – How Different Really Are QALYs From Life Years, Health Years in Total, and Equal Value Life Years?
Mar 10, 2025, 14:00 PM -
Evaluating the Value of Over-the-Counter Oseltamivir for Influenza: A Cost-Utility Analysis From U.S. Payer and Societal Perspectives
Mar 10, 2025, 14:00 PM -
Utilizing Machine Learning to Predict Survival Outcomes in Multiple Myeloma Patients with Diabetes: Insights from a 20-Year Cohort Study
Mar 10, 2025, 14:00 PM -
Enhancing Patient Engagement in Pharmacist-Provided Medication Therapy Management for Chronic Conditions
Mar 10, 2025, 14:00 PM -
The Economic Benefit of Biosimilars in North America: A Targeted Literature Review
Mar 10, 2025, 14:00 PM -
Qualitative Interviews to Characterize Disease and Treatment Burden at Baseline in Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for the Treatment of Glycogen Storage Disease Type Ia
Mar 10, 2025, 14:00 PM -
A Modern Approach for Constructing Decision Analytic Models in Microsoft Excel
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness (CEA) of Etonogestrel Subdermal Implant in a Brazilian Private Health Insurance
Mar 10, 2025, 14:00 PM -
Assessing Real-World Dosing Patterns for Vesicular Monoamine Transporter-2 Inhibitors (VMAT2i), Valbenazine and Deutetrabenazine, Among Patients with Tardive Dyskinesia (TD) in a Nationwide US Claims Database
Mar 10, 2025, 14:00 PM -
Budget Impact Analysis of Revumenib for the Treatment of Relapsed or Refractory Acute Leukemias With a KMT2A Translocation in the United States
Mar 10, 2025, 14:00 PM -
Psychometric Validation of the Sunlight Exposure Diary and Erythropoietic Protoporphyria Impact Questionnaire (EPIQ) Using Data from the AURORA Clinical Study in Erythropoietic Protoporphyria (EPP)
Mar 10, 2025, 14:00 PM -
Exploring Patterns of App-Based Tracking of Real-World Symptom and Treatment Experiences in Patients with Sickle Cell Disease and Cystic Fibrosis
Mar 10, 2025, 14:00 PM -
Unmet Needs and Evidence Gaps Among Patients with DLBCL treated with CAR-T Therapy: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Sunvozertinib as a Second-line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR exon20ins Mutation: An Economic Evaluation Based on MAIC
Mar 10, 2025, 14:00 PM -
Burden of Illness and Healthcare Resource Utilization (HCRU) for Chronic Obstructive Pulmonary Disease (COPD) in Ontario, Canada
Mar 10, 2025, 14:00 PM -
Pompe Disease in Sweden: A Real-World Evidence Study Investigating Healthcare Resource Utilisation and Costs
Mar 10, 2025, 14:00 PM -
Estimation of Drug Cost Reductions by Introducing formularies for An Employment-based Health Insurance Plan : A Simulation Using “Wellness-Star☆” Health Insurance Claims Database
Mar 10, 2025, 14:00 PM -
Measuring and Reporting Health-Related Quality of Life (HRQoL) in Locally Advanced/Metastatic Urothelial Cancer (La/mUC) Research: Capturing Outcomes That Really Matter to Patients
Mar 10, 2025, 14:00 PM -
A Checklist to Facilitate Reporting of Real-World Evidence (RWE) Submitted to Canada's Drug Agency (CDA-AMC) for a Drug Product Under Review
Mar 10, 2025, 14:00 PM -
Real-World Evidence on Health-Related Quality of Life in Older Women With Advanced Breast Cancer Treated With CDK 4/6 Inhibitors
Mar 10, 2025, 14:00 PM
